Amid the catastrophe caused by the new strain of the coronavirus, an important meeting was held today on the urgent use of the vaccine before it runs dry in all states of the country on January 2nd. A committee of experts from the Central Pharmaceutical Standards Control Organization (CDSCO) of the Government of India will take a decision after an important meeting to approve the emergency use of several vaccines, including Pfizer and Oxford. The meeting is also important because the World Health Organization has approved the Pfizer vaccine for emergency use and is on the list of cabinet committees of the Indian government.
According to news agency PTI, the Committee of Experts (CDSC) has considered the request of Serum Institute of India to allow emergency use of Covid-19 vaccine at Oxford University and request of India Biotech to allow emergency use of ‘Kovisin’.
The committee met this afternoon to consider allowing Serum Institute of India, Pfizer and Bharat Biotech Pvt Ltd to allow emergency use of the vaccines, the health ministry said in a statement. Please note that there was a meeting of this committee earlier on Wednesday. The expert committee on Covid-19 conducted additional detailed analysis submitted by the Serum Institute of India and Bharat Biotech.
Dry tomorrow all over the country
The center said on Thursday that the Covid-19 ticker rehearsal (dry-dry) will be conducted by all states and union territories on January 2. The exercise is proposed to be conducted at least three session sites in all state capitals. The Union Health Ministry said the exercise would be conducted in a few states even in districts where access is not easy and where there is no good arrangement of logistical facilities.
The central government has also asked all the states and union territories to start effective preparations for the Covid-19 vaccination exercise. Union Health Secretary Rajesh Bhushan on Thursday held a high-level meeting with the Principal Health Secretary and health officials from all the states and union territories and reviewed preparations at session sites for the Covid-19 vaccine.